Trials / Completed
CompletedNCT03342053
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7234292 (RG6042) | Intrathecal injection |
Timeline
- Start date
- 2018-01-02
- Primary completion
- 2019-10-08
- Completion
- 2019-10-08
- First posted
- 2017-11-14
- Last updated
- 2022-03-24
- Results posted
- 2021-01-19
Locations
9 sites across 3 countries: Canada, Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03342053. Inclusion in this directory is not an endorsement.